Accessibility Menu
NeoGenomics logo

NeoGenomics(NASDAQ) NEO

Current Price$13.90
Market Cap$1.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+434%
5 Year-70%
1 Year+116%
1 Month+8%
NeoGenomics last closing stock price
MetricPriceDate
Last closeUSD 13.892026-07-24
NeoGenomics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.93%USD 14.612026-07-17
1 month+7.67%USD 12.902026-06-24
3 month+67.55%USD 8.292026-04-24
Year to date+18.11%USD 11.762025-12-31
1 year+116.36%USD 6.422025-07-24
3 year-16.53%USD 16.642023-07-25
5 year-69.61%USD 45.712021-07-23
Since inception+434.23%USD 2.602001-11-23

NeoGenomics Financials at a Glance

Market Cap

$1.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$745.97M

Net Income (TTM)

-$99.21M

EPS (TTM)

-$0.77

P/E Ratio

-17.97

Dividend

$0.00

Beta (Volatility)

1.58 (High)

Price

$13.90

Volume

1,992,873.427

Open

$14.29

Previous Close

$13.89

Daily Range

$13.87 - $14.47

52-Week Range

$4.72 - $15.57

Estimated Earnings Date

Jul 28, 2026

NEO News

A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026
Group of medical practitioners having a seminar in board room

Why Shares of NeoGenomics Jumped Today

James HalleyFeb 23, 2023
GettyImages-970394878

Why Shares of NeoGenomics Jumped 53.9% This Week

James HalleyNov 11, 2022
time to buy

3 Top Small-Cap Stocks to Buy Right Now

James BrumleyMay 9, 2021
022 roller coaster

NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound

Maxx ChatskoAug 5, 2020
GettyImages-1236295594

3 Top Healthcare Stocks to Buy Right Now

Jim CrumlyJul 12, 2020
GettyImages-1138937146

2 Stocks to Buy and Hold for Decades

Prosper Junior BakinyMay 9, 2020
telemedicine

The Coronavirus Pandemic Will Test Invitae's Telemedicine Ambitions

Maxx ChatskoMay 5, 2020
Page 1

NEO: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeoGenomics

NeoGenomics helps doctors find and treat cancer using special medical tests. It runs labs that study patient samples to identify specific diseases. This helps medical teams choose the right treatments for their patients.

Inside the Testing Lab

  • Clinical Testing: Specialized laboratory services for pathologists and oncologists to diagnose cancer; includes technologies like cytogenetics and flow cytometry to study cell characteristics.
  • Pharma Services: Research support and clinical trial analysis for pharmaceutical companies; focuses on oncology drug discovery and commercialization.
  • Molecular and NGS: Genetic analysis of cells at the DNA and RNA level; uses next-generation sequencing (NGS) to identify specific genetic mutations.
  • RaDaR MRD Testing: Technology used to track signs of cancer after treatment; molecular residual disease (MRD) testing detects very low levels of malignant cells in blood samples.

Strategic Moves and Shifts

  • Acquired Pathline, LLC in April 2025 to expand laboratory presence and capabilities in the Northeast United States.
  • Sold the operating assets of Trapelo Health, LLC in December 2025 as part of an organizational restructuring.
  • Integrated liquid biopsy technology into the core portfolio following the 2021 acquisition of Inivata.
  • Achieved specific validation milestones in September 2025 related to expanded laboratory offerings.

How Operations Stand Out

NeoGenomics operates a specialized network of accredited laboratories across the United States and the United Kingdom. Its strategy focuses on providing rapid results and a comprehensive menu of advanced genetic tests to community-based oncology practices.

A Look at the Numbers

  • Revenue reached $186.7 million in Q1 2026, up 11.1% from the same period in 2025.
  • Operating loss reached $18.2 million in Q1 2026, which was a 34.4% improvement compared to the previous year.
  • Net loss reached $17.1 million in Q1 2026, representing a 34% year-over-year improvement.
  • Free cash flow was negative $13.1 million in Q1 2026, up 56% from negative $29.8 million in Q1 2025.

Bottom Line

NeoGenomics has transitioned toward high-growth molecular diagnostics and liquid biopsy services while narrowing its financial losses. The company continues to align its laboratory operations to support both community healthcare providers and pharmaceutical researchers.

AI Generated • May 1, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

2,500

CEO

Anthony P. Zook

Website

www.neogenomics.com

Headquarters

Fort Myers, FL 33912, US

NEO Financials

Key Financial Metrics (TTM)

Gross Margin

42.13%

Operating Margin

-13.94%

Net Income Margin

-13.30%

Return on Equity

-11.82%

Return on Capital

-5.05%

Return on Assets

-7.37%

Earnings Yield

-5.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

130.21M

Volume

1.99M

Avg. Volume

2.73M

Financials (TTM)

Gross Profit

$314.28M

Operating Income

-$104.02M

EBITDA

-$33.55M

Operating Cash Flow

$22.42M

Capital Expenditure

-$27.51M

Free Cash Flow

-$5.09M

Cash & ST Invst.

$146.14M

Total Debt

$408.53M

NeoGenomics Performance Analysis

NeoGenomics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 509,728,0005.2%
20232023-12-31USD 591,643,00016.1%
20242024-12-31USD 660,566,00011.6%
20252025-12-31USD 727,332,00010.1%
NeoGenomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.9%
Q32025-09-303.6%
Q42025-12-311.3%
Q12026-03-31-1.8%
NeoGenomics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.161568.5%
20232023-12-31USD -0.70-39.6%
20242024-12-31USD -0.62-11.3%
20252025-12-31USD -0.8435.7%
NeoGenomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-75.0%
Q32025-09-3040.0%
Q42025-12-3163.4%
Q12026-03-31-69.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$186.67M

+11.1%

Gross Profit

$80.86M

+10.4%

Gross Margin

43.32%

N/A

Market Cap

$1.81BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$723.46K

N/A

Employees

2,500

N/A

Net Income

-$17.11M

+34.0%

EBITDA

-$567.00K

+91.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$146.14M

-59.2%

Total Debt

$408.53M

-32.5%

Accounts Receivable

$167.42M

+10.7%

Inventory

$29.84M

+0.2%

Long Term Debt

$403.70M

+0.8%

Short Term Debt

$4.83M

-97.6%

Return on Assets

-7.37%

N/A

Return on Invested Capital

-8.24%

N/A

Free Cash Flow

-$13.14M

+56.0%

Operating Cash Flow

-$8.14M

+67.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACRSAclaris Therapeutics, Inc.
$5.23-4.56%
TKNOAlpha Teknova, Inc.
$4.97-4.42%
SMTISanara MedTech Inc.
$25.56+0.24%
SGMTSagimet Biosciences Inc.
$7.07+0.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$206.66-0.01%
QQQInvesco QQQ Trust
$683.85-0.01%
TSLATesla
$312.84-0.02%
SMCISuper Micro Computer
$30.14-0.03%

Questions About NEO

What is the current price of NeoGenomics?

NeoGenomics is trading at $13.89 per share.

What is the 52-week range for NeoGenomics?

Over the past 52 weeks, NeoGenomics has traded between $4.72 and $15.57.

How much debt does NeoGenomics have?

As of the most recent reporting period, NeoGenomics reported total debt of $408.53M.

How much cash does NeoGenomics have on hand?

NeoGenomics reported $146.14M in cash and cash equivalents in its most recent financial results.

What is NeoGenomics’s dividend yield?

NeoGenomics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services